Difference between revisions of "Amatuximab (MORAb-009)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "0 PubMed]" to "0/ PubMed]") |
||
(9 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | =Mechanism of action= | + | ==Mechanism of action== |
− | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=489384 NCI Drug Dictionary]: A humanized IgG1 monoclonal antibody directed against human mesothelin with potential antineoplastic activity. Amatuximab binds to mesothelin, triggering an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing tumor cells, which may result in tumor cell lysis. Mesothelin, a 40kDa cell surface glycoprotein, is overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinomas. | |
− | =Preliminary data= | + | ==Preliminary data== |
− | ==[[ | + | ===[[Malignant pleural mesothelioma]]=== |
− | # Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. [ | + | # Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252585/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25231400/ PubMed] |
+ | |||
+ | ==Also known as== | ||
+ | *'''Code name:''' MORAb-009 | ||
+ | |||
+ | [[Category:Drugs]] | ||
+ | [[Category:Intravenous medications]] | ||
− | |||
− | |||
− | |||
[[Category:Anti-mesothelin antibodies]] | [[Category:Anti-mesothelin antibodies]] | ||
− | [[Category:Mesothelioma medications]] | + | [[Category:Mesothelioma medications (investigational)]] |
− | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 13:22, 26 April 2023
Mechanism of action
From the NCI Drug Dictionary: A humanized IgG1 monoclonal antibody directed against human mesothelin with potential antineoplastic activity. Amatuximab binds to mesothelin, triggering an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing tumor cells, which may result in tumor cell lysis. Mesothelin, a 40kDa cell surface glycoprotein, is overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinomas.
Preliminary data
Malignant pleural mesothelioma
- Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. link to PMC article PubMed
Also known as
- Code name: MORAb-009